Extended-Interval Once-Daily Dosing of Aminoglycosides in Adult and Pediatric Patients with Cystic Fibrosis
Extended‐interval once‐daily dosing with the aminoglycoside tobramycin has been proven to be equally efficacious as traditional thrice‐daily dosing for treatment of the pulmonary exacerbations of cystic fibrosis in adults and children older than 5 years. The frequencies of acute ototoxicity and neph...
Gespeichert in:
| Veröffentlicht in: | Pharmacotherapy 2010-01, Vol.30 (1), p.95-108 |
|---|---|
| Hauptverfasser: | , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 108 |
|---|---|
| container_issue | 1 |
| container_start_page | 95 |
| container_title | Pharmacotherapy |
| container_volume | 30 |
| creator | Prescott Jr, William A. Nagel, Jerod L. |
| description | Extended‐interval once‐daily dosing with the aminoglycoside tobramycin has been proven to be equally efficacious as traditional thrice‐daily dosing for treatment of the pulmonary exacerbations of cystic fibrosis in adults and children older than 5 years. The frequencies of acute ototoxicity and nephrotoxicity do not appear to be significantly different between patients treated with once‐versus thrice‐daily dosing, and the risk of acute nephrotoxicity may actually be lower in pediatric patients when once‐daily dosing is used. Long‐term studies are needed to fully assess the impact that cumulative treatments with once‐daily dosing have on renal and auditory function. An increase in antimicrobial resistance has been suggested with once‐daily dosing in the cystic fibrosis population. The extended‐interval aminoglycoside dose should be determined based on previous therapeutic drug monitoring. If the patient is aminoglycoside (tobramycin) naïve, a dose of 10 mg/kg once/day is suggested, with the dose adjusted by using therapeutic drug monitoring to individualize therapy. |
| doi_str_mv | 10.1592/phco.30.1.95 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_journals_1618797083</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>3476622831</sourcerecordid><originalsourceid>FETCH-LOGICAL-c4280-cc834f7621c4820ccbff061676c8e7e3c9ff1155b030e7d2b046ace829cd00a63</originalsourceid><addsrcrecordid>eNp9kU1vEzEQhi0EoqFw44wsIW5sGNtre_eYJm1TqGiE-LpZXq-3dbvxBttpu_--rhLKjdNoRs87H-8g9JbAlPCaftpcmWHKcjKt-TM0IZXkRU1I-RxNgEpZAEB1gF7FeA1AiSjpS3RAARiUUk7QzfF9sr61bXHmkw23uscX3thioV0_4sUQnb_EQ4dna-eHy340udLaiJ3Hs3bbJ6x9i1e2dToFZ_BKJ2d9ivjOpSs8H2PKxRPXhCyLr9GLTvfRvtnHQ_Tj5Pj7fFmcX5yezWfnhSlpBYUxFSs7KSgxZUXBmKbrQBAhhamstMzUXUcI502-wcqWNlAKbWxFa9MCaMEO0ftd300Y_mxtTOp62AafRyoisj-1hIpl6uOOMnm5GGynNsGtdRgVAfXorHp0VrGcqJpn_N2-6bZZ2_YJ_mtlBj7sAR2N7rugvXHxH0d5yfNvMkd23J3r7fjfoWq1nH0TBLKm2GlcTPb-SaPDjRKSSa5-fT1Vn5c_j8iXxW_F2QNsiaB1</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1618797083</pqid></control><display><type>article</type><title>Extended-Interval Once-Daily Dosing of Aminoglycosides in Adult and Pediatric Patients with Cystic Fibrosis</title><source>MEDLINE</source><source>Wiley Journals</source><creator>Prescott Jr, William A. ; Nagel, Jerod L.</creator><creatorcontrib>Prescott Jr, William A. ; Nagel, Jerod L.</creatorcontrib><description>Extended‐interval once‐daily dosing with the aminoglycoside tobramycin has been proven to be equally efficacious as traditional thrice‐daily dosing for treatment of the pulmonary exacerbations of cystic fibrosis in adults and children older than 5 years. The frequencies of acute ototoxicity and nephrotoxicity do not appear to be significantly different between patients treated with once‐versus thrice‐daily dosing, and the risk of acute nephrotoxicity may actually be lower in pediatric patients when once‐daily dosing is used. Long‐term studies are needed to fully assess the impact that cumulative treatments with once‐daily dosing have on renal and auditory function. An increase in antimicrobial resistance has been suggested with once‐daily dosing in the cystic fibrosis population. The extended‐interval aminoglycoside dose should be determined based on previous therapeutic drug monitoring. If the patient is aminoglycoside (tobramycin) naïve, a dose of 10 mg/kg once/day is suggested, with the dose adjusted by using therapeutic drug monitoring to individualize therapy.</description><identifier>ISSN: 0277-0008</identifier><identifier>EISSN: 1875-9114</identifier><identifier>DOI: 10.1592/phco.30.1.95</identifier><identifier>PMID: 20030477</identifier><identifier>CODEN: PHPYDQ</identifier><language>eng</language><publisher>Oxford, UK: Blackwell Publishing Ltd</publisher><subject>Adolescent ; Adult ; Aged ; aminoglycoside ; Aminoglycosides - administration & dosage ; Aminoglycosides - adverse effects ; Aminoglycosides - pharmacokinetics ; Aminoglycosides - therapeutic use ; Anti-Bacterial Agents - administration & dosage ; Anti-Bacterial Agents - adverse effects ; Anti-Bacterial Agents - pharmacokinetics ; Anti-Bacterial Agents - therapeutic use ; Biological and medical sciences ; Child ; Clinical Trials as Topic ; cystic fibrosis ; Cystic Fibrosis - complications ; Drug Administration Schedule ; Drug Monitoring ; EID ; Errors of metabolism ; extended-interval dosing ; Humans ; infectious disease ; Medical sciences ; Metabolic diseases ; Middle Aged ; Miscellaneous hereditary metabolic disorders ; once-daily dosing ; pediatrics ; pharmacokinetics ; Pharmacology. Drug treatments ; pulmonary exacerbations ; Respiratory Tract Infections - complications ; Respiratory Tract Infections - drug therapy ; Tobramycin - administration & dosage ; Tobramycin - adverse effects ; Tobramycin - pharmacokinetics ; Tobramycin - therapeutic use ; Treatment Outcome ; Young Adult</subject><ispartof>Pharmacotherapy, 2010-01, Vol.30 (1), p.95-108</ispartof><rights>2010 Pharmacotherapy Publications Inc.</rights><rights>2015 INIST-CNRS</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c4280-cc834f7621c4820ccbff061676c8e7e3c9ff1155b030e7d2b046ace829cd00a63</citedby><cites>FETCH-LOGICAL-c4280-cc834f7621c4820ccbff061676c8e7e3c9ff1155b030e7d2b046ace829cd00a63</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1592%2Fphco.30.1.95$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1592%2Fphco.30.1.95$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>314,780,784,1417,4024,27923,27924,27925,45574,45575</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=22545875$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/20030477$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Prescott Jr, William A.</creatorcontrib><creatorcontrib>Nagel, Jerod L.</creatorcontrib><title>Extended-Interval Once-Daily Dosing of Aminoglycosides in Adult and Pediatric Patients with Cystic Fibrosis</title><title>Pharmacotherapy</title><addtitle>Pharmacotherapy</addtitle><description>Extended‐interval once‐daily dosing with the aminoglycoside tobramycin has been proven to be equally efficacious as traditional thrice‐daily dosing for treatment of the pulmonary exacerbations of cystic fibrosis in adults and children older than 5 years. The frequencies of acute ototoxicity and nephrotoxicity do not appear to be significantly different between patients treated with once‐versus thrice‐daily dosing, and the risk of acute nephrotoxicity may actually be lower in pediatric patients when once‐daily dosing is used. Long‐term studies are needed to fully assess the impact that cumulative treatments with once‐daily dosing have on renal and auditory function. An increase in antimicrobial resistance has been suggested with once‐daily dosing in the cystic fibrosis population. The extended‐interval aminoglycoside dose should be determined based on previous therapeutic drug monitoring. If the patient is aminoglycoside (tobramycin) naïve, a dose of 10 mg/kg once/day is suggested, with the dose adjusted by using therapeutic drug monitoring to individualize therapy.</description><subject>Adolescent</subject><subject>Adult</subject><subject>Aged</subject><subject>aminoglycoside</subject><subject>Aminoglycosides - administration & dosage</subject><subject>Aminoglycosides - adverse effects</subject><subject>Aminoglycosides - pharmacokinetics</subject><subject>Aminoglycosides - therapeutic use</subject><subject>Anti-Bacterial Agents - administration & dosage</subject><subject>Anti-Bacterial Agents - adverse effects</subject><subject>Anti-Bacterial Agents - pharmacokinetics</subject><subject>Anti-Bacterial Agents - therapeutic use</subject><subject>Biological and medical sciences</subject><subject>Child</subject><subject>Clinical Trials as Topic</subject><subject>cystic fibrosis</subject><subject>Cystic Fibrosis - complications</subject><subject>Drug Administration Schedule</subject><subject>Drug Monitoring</subject><subject>EID</subject><subject>Errors of metabolism</subject><subject>extended-interval dosing</subject><subject>Humans</subject><subject>infectious disease</subject><subject>Medical sciences</subject><subject>Metabolic diseases</subject><subject>Middle Aged</subject><subject>Miscellaneous hereditary metabolic disorders</subject><subject>once-daily dosing</subject><subject>pediatrics</subject><subject>pharmacokinetics</subject><subject>Pharmacology. Drug treatments</subject><subject>pulmonary exacerbations</subject><subject>Respiratory Tract Infections - complications</subject><subject>Respiratory Tract Infections - drug therapy</subject><subject>Tobramycin - administration & dosage</subject><subject>Tobramycin - adverse effects</subject><subject>Tobramycin - pharmacokinetics</subject><subject>Tobramycin - therapeutic use</subject><subject>Treatment Outcome</subject><subject>Young Adult</subject><issn>0277-0008</issn><issn>1875-9114</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2010</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp9kU1vEzEQhi0EoqFw44wsIW5sGNtre_eYJm1TqGiE-LpZXq-3dbvxBttpu_--rhLKjdNoRs87H-8g9JbAlPCaftpcmWHKcjKt-TM0IZXkRU1I-RxNgEpZAEB1gF7FeA1AiSjpS3RAARiUUk7QzfF9sr61bXHmkw23uscX3thioV0_4sUQnb_EQ4dna-eHy340udLaiJ3Hs3bbJ6x9i1e2dToFZ_BKJ2d9ivjOpSs8H2PKxRPXhCyLr9GLTvfRvtnHQ_Tj5Pj7fFmcX5yezWfnhSlpBYUxFSs7KSgxZUXBmKbrQBAhhamstMzUXUcI502-wcqWNlAKbWxFa9MCaMEO0ftd300Y_mxtTOp62AafRyoisj-1hIpl6uOOMnm5GGynNsGtdRgVAfXorHp0VrGcqJpn_N2-6bZZ2_YJ_mtlBj7sAR2N7rugvXHxH0d5yfNvMkd23J3r7fjfoWq1nH0TBLKm2GlcTPb-SaPDjRKSSa5-fT1Vn5c_j8iXxW_F2QNsiaB1</recordid><startdate>201001</startdate><enddate>201001</enddate><creator>Prescott Jr, William A.</creator><creator>Nagel, Jerod L.</creator><general>Blackwell Publishing Ltd</general><general>Pharmacotherapy</general><general>Wiley Subscription Services, Inc</general><scope>BSCLL</scope><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7QP</scope><scope>7TK</scope><scope>K9.</scope></search><sort><creationdate>201001</creationdate><title>Extended-Interval Once-Daily Dosing of Aminoglycosides in Adult and Pediatric Patients with Cystic Fibrosis</title><author>Prescott Jr, William A. ; Nagel, Jerod L.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c4280-cc834f7621c4820ccbff061676c8e7e3c9ff1155b030e7d2b046ace829cd00a63</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2010</creationdate><topic>Adolescent</topic><topic>Adult</topic><topic>Aged</topic><topic>aminoglycoside</topic><topic>Aminoglycosides - administration & dosage</topic><topic>Aminoglycosides - adverse effects</topic><topic>Aminoglycosides - pharmacokinetics</topic><topic>Aminoglycosides - therapeutic use</topic><topic>Anti-Bacterial Agents - administration & dosage</topic><topic>Anti-Bacterial Agents - adverse effects</topic><topic>Anti-Bacterial Agents - pharmacokinetics</topic><topic>Anti-Bacterial Agents - therapeutic use</topic><topic>Biological and medical sciences</topic><topic>Child</topic><topic>Clinical Trials as Topic</topic><topic>cystic fibrosis</topic><topic>Cystic Fibrosis - complications</topic><topic>Drug Administration Schedule</topic><topic>Drug Monitoring</topic><topic>EID</topic><topic>Errors of metabolism</topic><topic>extended-interval dosing</topic><topic>Humans</topic><topic>infectious disease</topic><topic>Medical sciences</topic><topic>Metabolic diseases</topic><topic>Middle Aged</topic><topic>Miscellaneous hereditary metabolic disorders</topic><topic>once-daily dosing</topic><topic>pediatrics</topic><topic>pharmacokinetics</topic><topic>Pharmacology. Drug treatments</topic><topic>pulmonary exacerbations</topic><topic>Respiratory Tract Infections - complications</topic><topic>Respiratory Tract Infections - drug therapy</topic><topic>Tobramycin - administration & dosage</topic><topic>Tobramycin - adverse effects</topic><topic>Tobramycin - pharmacokinetics</topic><topic>Tobramycin - therapeutic use</topic><topic>Treatment Outcome</topic><topic>Young Adult</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Prescott Jr, William A.</creatorcontrib><creatorcontrib>Nagel, Jerod L.</creatorcontrib><collection>Istex</collection><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Calcium & Calcified Tissue Abstracts</collection><collection>Neurosciences Abstracts</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><jtitle>Pharmacotherapy</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Prescott Jr, William A.</au><au>Nagel, Jerod L.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Extended-Interval Once-Daily Dosing of Aminoglycosides in Adult and Pediatric Patients with Cystic Fibrosis</atitle><jtitle>Pharmacotherapy</jtitle><addtitle>Pharmacotherapy</addtitle><date>2010-01</date><risdate>2010</risdate><volume>30</volume><issue>1</issue><spage>95</spage><epage>108</epage><pages>95-108</pages><issn>0277-0008</issn><eissn>1875-9114</eissn><coden>PHPYDQ</coden><abstract>Extended‐interval once‐daily dosing with the aminoglycoside tobramycin has been proven to be equally efficacious as traditional thrice‐daily dosing for treatment of the pulmonary exacerbations of cystic fibrosis in adults and children older than 5 years. The frequencies of acute ototoxicity and nephrotoxicity do not appear to be significantly different between patients treated with once‐versus thrice‐daily dosing, and the risk of acute nephrotoxicity may actually be lower in pediatric patients when once‐daily dosing is used. Long‐term studies are needed to fully assess the impact that cumulative treatments with once‐daily dosing have on renal and auditory function. An increase in antimicrobial resistance has been suggested with once‐daily dosing in the cystic fibrosis population. The extended‐interval aminoglycoside dose should be determined based on previous therapeutic drug monitoring. If the patient is aminoglycoside (tobramycin) naïve, a dose of 10 mg/kg once/day is suggested, with the dose adjusted by using therapeutic drug monitoring to individualize therapy.</abstract><cop>Oxford, UK</cop><pub>Blackwell Publishing Ltd</pub><pmid>20030477</pmid><doi>10.1592/phco.30.1.95</doi><tpages>14</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0277-0008 |
| ispartof | Pharmacotherapy, 2010-01, Vol.30 (1), p.95-108 |
| issn | 0277-0008 1875-9114 |
| language | eng |
| recordid | cdi_proquest_journals_1618797083 |
| source | MEDLINE; Wiley Journals |
| subjects | Adolescent Adult Aged aminoglycoside Aminoglycosides - administration & dosage Aminoglycosides - adverse effects Aminoglycosides - pharmacokinetics Aminoglycosides - therapeutic use Anti-Bacterial Agents - administration & dosage Anti-Bacterial Agents - adverse effects Anti-Bacterial Agents - pharmacokinetics Anti-Bacterial Agents - therapeutic use Biological and medical sciences Child Clinical Trials as Topic cystic fibrosis Cystic Fibrosis - complications Drug Administration Schedule Drug Monitoring EID Errors of metabolism extended-interval dosing Humans infectious disease Medical sciences Metabolic diseases Middle Aged Miscellaneous hereditary metabolic disorders once-daily dosing pediatrics pharmacokinetics Pharmacology. Drug treatments pulmonary exacerbations Respiratory Tract Infections - complications Respiratory Tract Infections - drug therapy Tobramycin - administration & dosage Tobramycin - adverse effects Tobramycin - pharmacokinetics Tobramycin - therapeutic use Treatment Outcome Young Adult |
| title | Extended-Interval Once-Daily Dosing of Aminoglycosides in Adult and Pediatric Patients with Cystic Fibrosis |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-29T00%3A25%3A17IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Extended-Interval%20Once-Daily%20Dosing%20of%20Aminoglycosides%20in%20Adult%20and%20Pediatric%20Patients%20with%20Cystic%20Fibrosis&rft.jtitle=Pharmacotherapy&rft.au=Prescott%20Jr,%20William%20A.&rft.date=2010-01&rft.volume=30&rft.issue=1&rft.spage=95&rft.epage=108&rft.pages=95-108&rft.issn=0277-0008&rft.eissn=1875-9114&rft.coden=PHPYDQ&rft_id=info:doi/10.1592/phco.30.1.95&rft_dat=%3Cproquest_cross%3E3476622831%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1618797083&rft_id=info:pmid/20030477&rfr_iscdi=true |